Pfizer Ltd. — Board/Management Information 2024

Nov 5, 2024

==> picture [100 x 41] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 5, 2024

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation regarding change in Senior Management Personnel of the Company.

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), we hereby inform you the following changes in the Senior Management Personnel (“SMP”) of the Company:

• 1) Mr. Deepak Rakheja, Category Lead – Internal Medicine has been appointed as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel.

• 2) Appointment of Mr. Prashant Mahalingam as Category Lead – Internal Medicine effective November 7, 2024. Mr. Prashant Mahalingam shall be a Senior Management Personnel effective the said date.

• 3) Resignation of Mr. Debashish Roy, Director – Patient & Healthcare Experience Studio from the services of the Company with effect from November 29, 2024 to pursue opportunities outside Pfizer Limited. Mr. Debashish Roy shall accordingly cease to be a Senior Management Personnel effective the said date.

Additional details required to be disclosed pursuant to the SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure A (profile of the Appointees) and Annexure B (Resignation letter).

Request you to please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited PRAJEET Digitally signed by PRAJEET NAIR NAIR Date: 2024.11.05 18:53:41 +05'30' Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

Annexure A

Sr. no	Particulars		Details	Details
1.	Name		Mr. Prashant Mahalingam	Mr. Deepak Rakheja
2.	Reasons for change		Appointment of Mr. Prashant Mahalingam as Category Lead – Internal Medicine effective November 7, 2024. He will be a part of the Senior Management Personnel effective the said date.	Appointment of Mr. Deepak Rakheja, as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel.
3.	Date of Appointment	~~and Term~~	November 7, 2024	November 7, 2024
4.	Affirmation as per List/Comp/14/2018-19 dated June 20, 2018		Not Applicable	Not Applicable
5.	Relationship inter-se Directors / Key Managerial Personnel / Senior Management Personnel		Mr. Prashant Mahalingam is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.	Mr. Deepak Rakheja is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.
6.	Number of Shares held in the Company		Nil	Nil
7.	Brief Profile		Mr. Prashant Mahalingam holds a Bachelors in Technology (Chemical Engineering) from IIT Madras, Post Graduate Degree in Management from IIM Calcutta and Executive Education Innovation Consortium from Tuck School of Business, University of Dartmouth. Mr. Mahalingam is a versatile and transformative business leader with over 25 years of experience across General Management, Sales, Marketing, Human Resources, Supply Chain, Digital Transformation, Analytics, and E-Commerce, primarily in the FMCG and Pharmaceutical sectors. Mr. Mahalingam joins the Company from Dr. Reddy’s Laboratories Limited (DRL), where he served as the Cluster Head for the Acute Therapies (RX) and Consumer Health business. Prior to his role with DRL Mr. Mahalingam served as Commercial Head for Johnson & Johnson’s Consumer health business in Malaysia and Singapore markets. Mr. Mahalingam has significant experience in leading large teams, turning around businesses to deliver market-beating and sustainable growth, and spearheading new innovation-led digital ventures.	Mr. Deepak Rakheja holds Master’s in Business Administration Degree from HEC Paris Business School. Mr. Rakheja also holds a Master of Economics Degree from University of Delhi. Mr. Deepak Rakheja has during his 15 years of tenure with Pfizer, helmed roles of increased scope, responsibility & complexity, including Category Lead – Internal Medicine, Commercial roles, Sales Logistics & Demand Management, Business Operations, Field Force Effectiveness, Training, and Commercial Compliance. Mr. Rakheja also lead Pfizer’s Global Commercial Operations (GCO) for Africa, Middle East & India. Prior to this he had also served as the Commercial Director for Growth Markets (Iran, Iraq, Syria & Yemen) and the Strategic Alliances Gulf Levant Markets.

Annexure - B

==> picture [118 x 28] intentionally omitted <==

==> picture [49 x 5] intentionally omitted <==